Candida Endophthalmitis: Focus on Current and Future Antifungal Treatment Options
暂无分享,去创建一个
[1] M. Choti,et al. Triazole Cross-Resistance among Candida spp.: Case Report, Occurrence among Bloodstream Isolates, and Implications for Antifungal Therapy , 2006, Journal of Clinical Microbiology.
[2] S. Filler,et al. Current treatment strategies for disseminated candidiasis. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] H. Takebayashi,et al. Relation between stage of endogenous fungal endophthalmitis and prognosis , 2006, Graefe's Archive for Clinical and Experimental Ophthalmology.
[4] E. Thiel,et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. , 2005, Blood.
[5] D. Andes,et al. Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[6] J. Vazquez,et al. Anidulafungin: a new echinocandin with a novel profile. , 2005, Clinical therapeutics.
[7] P. Moss,et al. Use of voriconazole in candida retinitis , 2005, Eye.
[8] J. Bradley,et al. Candida Glabrata Endophthalmitis Treated Successfully with Caspofungin , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] W. Mieler,et al. Management of endogenous fungal endophthalmitis with voriconazole and caspofungin. , 2005, American journal of ophthalmology.
[10] J. Giaconi,et al. In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens. , 2004, American journal of ophthalmology.
[11] Lee H. Harrison,et al. Incidence of Bloodstream Infections Due to Candida Species and In Vitro Susceptibilities of Isolates Collected from 1998 to 2000 in a Population-Based Active Surveillance Program , 2004, Journal of Clinical Microbiology.
[12] H. Flynn,et al. Culture-proven endogenous endophthalmitis: clinical features and visual acuity outcomes. , 2004, American journal of ophthalmology.
[13] J. Sobel,et al. Guidelines for treatment of candidiasis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[14] Judy E. Kim,et al. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. , 2004, Archives of ophthalmology.
[15] H. Flynn,et al. Current Management of Endophthalmitis , 2004, International ophthalmology clinics.
[16] J. Cleary,et al. Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United States , 2003, Antimicrobial Agents and Chemotherapy.
[17] N. Wiederhold,et al. The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy , 2003, Expert opinion on investigational drugs.
[18] John W. Miller,et al. Retinal Lesions as Clues to Disseminated Bacterial and Candidal Infections: Frequency, Natural History, and Etiology , 2003, Medicine.
[19] P. Kaiser,et al. Endogenous Endophthalmitis: An 18-Year Review of Culture-Positive Cases at a Tertiary Care Center , 2003, Medicine.
[20] J. Perfect,et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. , 2002, The New England journal of medicine.
[21] K. Rohrer,et al. Ocular Distribution of Intravenously Administered Lipid Formulations of Amphotericin B in a Rabbit Model , 2002, Antimicrobial Agents and Chemotherapy.
[22] B. Potoski,et al. The safety of voriconazole. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[23] T. Walsh,et al. Comparative Antifungal Activities and Plasma Pharmacokinetics of Micafungin (FK463) against Disseminated Candidiasis and Invasive Pulmonary Aspergillosis in Persistently Neutropenic Rabbits , 2002, Antimicrobial Agents and Chemotherapy.
[24] M. Pfaller,et al. In Vitro Activities of Ravuconazole and Voriconazole Compared with Those of Four Approved Systemic Antifungal Agents against 6,970 Clinical Isolates of Candida spp , 2002, Antimicrobial Agents and Chemotherapy.
[25] S. Piscitelli,et al. Compartmental Pharmacokinetics and Tissue Distribution of the Antifungal Echinocandin Lipopeptide Micafungin (FK463) in Rabbits , 2001, Antimicrobial Agents and Chemotherapy.
[26] R. Wyse,et al. Pharmacotherapy of fungal eye infections , 2001, Expert opinion on pharmacotherapy.
[27] S. Piscitelli,et al. Pharmacokinetic and Pharmacodynamic Modeling of Anidulafungin (LY303366): Reappraisal of Its Efficacy in Neutropenic Animal Models of Opportunistic Mycoses Using Optimal Plasma Sampling , 2001, Antimicrobial Agents and Chemotherapy.
[28] M. Avison,et al. Interscience Conference on Antimicrobial Agents and Chemotherapy , 2001 .
[29] M. Klepser,et al. Postantifungal Effects of Echinocandin, Azole, and Polyene Antifungal Agents against Candida albicans andCryptococcus neoformans , 2000, Antimicrobial Agents and Chemotherapy.
[30] D. Wilks,et al. Successful treatment of Candida glabrata endophthalmitis with amphotericin B lipid complex (ABLC). , 2000, The Journal of infection.
[31] C. Lowder,et al. Should all patients with candidaemia have an ophthalmic examination to rule out ocular candidiasis? , 2000, Eye.
[32] V. Yu,et al. Antimicrobial Therapy and Vaccines , 1999 .
[33] J. Kylstra,et al. Worsening of endogenous Candida albicans endophthalmitis during therapy with intravenous lipid complex amphotericin B. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[34] D. Slain. Lipid‐Based Amphotericin B for the Treatment of Fungal Infections , 1999, Pharmacotherapy.
[35] J. Bradley,et al. Obturator internus muscle abscess in children: report of seven cases and review. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[36] Carpenter,et al. Candida albicans endophthalmitis in brown heroin addicts: response to early vitrectomy preceded and followed by antifungal therapy. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[37] Michael H. Miller,et al. Comparison of fluconazole pharmacokinetics in serum, aqueous humor, vitreous humor, and cerebrospinal fluid following a single dose and at steady state. , 1998, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.
[38] C. Y. Yu,et al. Voriconazole against fluconazole-susceptible and resistant candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole. , 1998, The Journal of antimicrobial chemotherapy.
[39] W. Smiddy. Treatment outcomes of endogenous fungal endophthalmitis. , 1998, Current opinion in ophthalmology.
[40] H. Flynn,et al. Treatment outcomes in a 10-year study of endogenous fungal endophthalmitis. , 1997, Ophthalmic surgery and lasers.
[41] O. Lortholary,et al. Intravenous penetration of fluconazole during endophthalmitis. , 1997, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[42] W. Smiddy,et al. Vitrectomy and systemic fluconazole for treatment of endogenous fungal endophthalmitis. , 1996, Ophthalmic surgery and lasers.
[43] S. Lightman,et al. Candida endophthalmitis. , 1995, The British journal of ophthalmology.
[44] B. Kubak,et al. Treatment of ocular fungal infections with oral fluconazole. , 1995, American journal of ophthalmology.
[45] S. Walmsley,et al. Use of fluconazole in the treatment of candidal endophthalmitis. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[46] M. Levenstein,et al. A Randomized Trial Comparing Fluconazole with Amphotericin B for the Treatment of Candidemia in Patients without Neutropenia , 1994 .
[47] R. Devenyi,et al. Mortality of hospitalized patients with Candida endophthalmitis. , 1994, Archives of internal medicine.
[48] A. Eller,et al. Intraocular candidiasis in patients with candidemia. Clinical implications derived from a prospective multicenter study. , 1994, Ophthalmology.
[49] S. F. Urbak,et al. Fluconazole in the management of fungal ocular infections. , 1994, Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde.
[50] J. Ruskin,et al. Failure of therapy with fluconazole for candidal endophthalmitis. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[51] A. R. Noriega,et al. Fluconazole in the management of endophthalmitis in disseminated candidosis of heroin addicts , 1993, Mycoses.
[52] J. Miro,et al. Disseminated candidiasis in addicts who use brown heroin: report of 83 cases and review. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[53] A. Chignell. Endogenous Candida Endophthalmitis , 1992, Journal of the Royal Society of Medicine.
[54] R. Guthoff,et al. Endogene Candida-Endophthalmitis bei einem Drogenabhängigen : intravenöse Therapie mit liposomal verkapseltem Amphotericin B , 1992 .
[55] D. McQuillen,et al. Invasive infections due to Candida krusei: report of ten cases of fungemia that include three cases of endophthalmitis. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[56] J. B. Dickey,et al. Endogenous Candida endophthalmitis after intravenous anesthesia with propofol. , 1991, Archives of ophthalmology.
[57] S. Filler,et al. Comparison of fluconazole and amphotericin B for treatment of disseminated candidiasis and endophthalmitis in rabbits , 1991, Antimicrobial Agents and Chemotherapy.
[58] W. S. Head,et al. Ocular uptake of fluconazole following oral administration. , 1990, Archives of ophthalmology.
[59] B. Strom,et al. Risk factors for nosocomial candidemia: a case-control study in adults without leukemia. , 1989, The American journal of medicine.
[60] R. Brooks,et al. Prospective study of Candida endophthalmitis in hospitalized patients with candidemia. , 1989, Archives of internal medicine.
[61] S. Pflugfelder,et al. Complications of intraocular antimicrobial agents. , 1989, International ophthalmology clinics.
[62] R F Woolson,et al. Hospital-acquired candidemia. The attributable mortality and excess length of stay. , 1988, Archives of internal medicine.
[63] J. Perfect,et al. Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis , 1987, Antimicrobial Agents and Chemotherapy.
[64] W. S. Head,et al. Intraocular penetration of systemically administered antifungal agents. , 1985, Current eye research.
[65] G. Chader,et al. PHARMACOLOGY OF THE EYE , 1984, Handbook of Experimental Pharmacology.
[66] A. Espinel-Ingroff,et al. Penetration of amphotericin B into the human eye. , 1983, The Journal of infectious diseases.
[67] D. Henderson,et al. Hematogenous candida endophthalmitis in patients receiving parenteral hyperalimentation fluids. , 1981, The Journal of infectious diseases.
[68] L. M. Aiello,et al. Closed vitreous surgery. XVII. Results and complications of pars plana vitrectomy. , 1980, Archives of ophthalmology.
[69] A. Friedman,et al. Ocular penetration of 5-fluorocytosine. , 1978, Investigative ophthalmology & visual science.
[70] R. Luke. ENTEROTOXIN‐PRODUCING Escherichia coli AND DIARRHOEA AMONG NEWBORN BABIES IN DARWIN , 1978, The Medical journal of Australia.
[71] J. O. Morrison,et al. Experimental hematogenous endophthalmitis due to Candida: species variation in ocular pathogenicity. , 1977, The Journal of infectious diseases.
[72] B. Jones,et al. Principles in the management of oculomycosis. XXXI Edward Jackson memorial lecture. , 1975, American journal of ophthalmology.
[73] W. Green,et al. Intravitreal amphotericin B toxicity. , 1974, American journal of ophthalmology.
[74] J. Edwards,et al. OCULAR MANIFESTATIONS OF CANDIDA SEPTICEMIA: REVIEW OF SEVENTY-SIX CASES OF HEMATOGENOUS CANDIDA ENDOPHTHALMITIS , 1974, Medicine.
[75] D. Robertson,et al. Endogenous Candida oculomycosis. Report of two patients treated with flucytosine. , 1974, Archives of ophthalmology.
[76] J. R. Griffin,et al. Blood-borne Candida endophthalmitis. A clinical and pathologic study of 21 cases. , 1973, Archives of ophthalmology.
[77] E. Schubert. [Fungal infections of the eye]. , 1970, Klinische Monatsblatter fur Augenheilkunde.
[78] A. B. Richards,et al. Corneal and intra-ocular infection by Candida albicans treated with 5-fluorocytosine. , 1970, Transactions of the ophthalmological societies of the United Kingdom.
[79] W. Green,et al. OCULAR PENETRATION OF AMPHOTERICIN B: A REPORT OF LABORATORY STUDIES AND A CASE REPORT OF POSTSURGICAL CEPHALOSPORIUM ENDOPHTHALMITIS. , 1965, Archives of ophthalmology.